• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.

    2/17/26 4:26:58 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INBX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Inhibrx Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    45720N103

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,454,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,454,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,454,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,454,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,454,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,454,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,351,744.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,351,744.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,351,744.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,284,726.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,284,726.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,284,726.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,284,726.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,284,726.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,284,726.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    KAVRA 104 LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    67,018.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    67,018.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    67,018.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    102,864.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    102,864.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    102,864.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    102,864.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    102,864.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    102,864.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown (Aggregator) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    102,864.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    102,864.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    102,864.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,454,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,454,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,454,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,454,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,454,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,454,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    45720N103


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,454,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,454,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,454,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inhibrx Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    11025 N. Torrey Pines Road, Suite 140, La Jolla, California, 92037
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), KAVRA 104 LLC ("KAVRA 104"), Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, KAVRA 104, VGOD GP and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    45720N103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    This Statement on Schedule 13G relates to shares of Common Stock held directly by VGOP, KAVRA 104 and VGOD, and warrants to purchase shares of Common Stock with an exercise price of $0.0001 per share (the "Warrants") held directly by VGOP. VGOP directly owns 1,267,823 shares of Common Stock and Warrants with the right to purchase 259,692 shares of Common Stock. KAVRA 104 directly owns 67,018 shares of Common Stock. VGOD directly owns 102,864 shares of Common Stock. However, the terms of the Warrants provide that no holder of Warrants shall have the right to exercise any portion of the Warrants to the extent that, after giving effect to such issuance after exercise, such holder of Warrants (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately following exercise (the "Blocker"). Any holder of Warrants, upon notice to the Issuer, may increase or decrease the Blocker, subject to a maximum of 19.99%, but any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer. Accordingly, the amount of shares of Common Stock reported as beneficially owned by the Reporting Persons set forth herein excludes shares of Common Stock that the Reporting Persons do not currently have the right to purchase upon exercise of the Warrants held directly by VGOP due to the Blocker. VGI: 1,454,608 VGI provides managerial services to VGOP, KAVRA 104 and VGOD. VGI has the authority to dispose of and vote the shares of Common Stock directly held by VGOP, KAVRA 104 and VGOD and the shares of Common Stock that VGOP has the right to purchase upon exercise of the Warrants. VGI does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Common Stock directly held by VGOP, KAVRA 104 and VGOD and the shares of Common Stock that VGOP has the right to purchase upon exercise of the Warrants. VGI beneficially owns 1,454,608 shares of Common Stock consisting of (i) 1,267,823 shares of Common Stock directly owned by VGOP, (ii) 67,018 shares of Common Stock directly owned by KAVRA 104, (iii) 102,864 shares of Common Stock directly owned by VGOD and (iv) 16,903 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. Opportunities Parent: 1,454,608 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants), and KAVRA 104, and is the sole member of VGOD GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP (which consists of the shares of Common Stock directly held by VGOD). Opportunities Parent does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock directly held by VGOP, KAVRA 104 and VGOD and the shares of Common Stock that VGOP has the right to purchase upon exercise of the Warrants. Opportunities Parent beneficially owns 1,454,608 shares of Common Stock consisting of (i) 1,267,823 shares of Common Stock directly owned by VGOP, (ii) 67,018 shares of Common Stock directly owned by KAVRA 104, (iii) 102,864 shares of Common Stock directly owned by VGOD and (iv) 16,903 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. Opportunities GP: 1,351,744 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. The membership interests of KAVRA 104 are held by Viking Global Opportunities Intermediate LP and Viking Global Opportunities LP. Accordingly, Opportunities GP has the authority to dispose of and vote the shares of Common Stock directly held by KAVRA 104. Opportunities GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock directly held by VGOP and KAVRA 104 and the shares of Common Stock that VGOP has the right to purchase upon exercise of the Warrants. Opportunities GP beneficially owns 1,351,744 shares of Common Stock consisting of (i) 1,267,823 shares of Common Stock directly owned by VGOP, (ii) 67,018 shares of Common Stock directly owned by KAVRA 104 and (iii) 16,903 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. Opportunities Portfolio GP: 1,284,726 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP beneficially owns 1,284,726 shares of Common Stock consisting of 1,267,823 shares of Common Stock directly owned by VGOP and 16,903 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. VGOP: 1,284,726 VGOP has the authority to dispose of and vote the shares of Common Stock that it directly owns or has the right to purchase upon exercise of the Warrants directly owned by it, subject to the Blocker, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. KAVRA 104: 67,018 KAVRA 104 has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by Opportunities GP and its sole member, Opportunities Parent, and by VGI, an affiliate of Opportunities GP, which provides managerial services to KAVRA 104. The membership interests of KAVRA 104 are held by Viking Global Opportunities Intermediate LP and Viking Global Opportunities LP. Opportunities GP is the general partner of each of Viking Global Opportunities LP and Viking Global Opportunities Intermediate LP. VGOD GP: 102,864 VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP, which consists of the shares of Common Stock that VGOD directly owns. In addition, VGOD GP is the general partner of each of Viking Global Opportunities Drawdown (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, VGOD GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns. VGOD GP beneficially owns 102,864 shares of Common Stock consisting of 102,864 shares of Common Stock directly owned by VGOD. VGOD Portfolio GP: 102,864 VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the shares of Common Stock that VGOD directly owns. VGOD Portfolio GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 of the Act, VGOD Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns. VGOD Portfolio GP beneficially owns 102,864 shares of Common Stock consisting of 102,864 shares of Common Stock directly owned by VGOD. VGOD: 102,864 VGOD has the authority to dispose of and vote the 102,864 shares of Common Stock that it directly owns, which power may be exercised by its general partner, VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD. Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 1,454,608 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, each may be deemed to beneficially own the shares of Common Stock directly held by VGOP, KAVRA 104 and VGOD and the shares of Common Stock that VGOP has the right to purchase upon exercise of the Warrants. Each of Mr. Halvorsen, Mr. Ott and Ms. Shabet beneficially owns 1,454,608 shares of Common Stock consisting of (i) 1,267,823 shares of Common Stock directly owned by VGOP, (ii) 67,018 shares of Common Stock directly owned by KAVRA 104, (iii) 102,864 shares of Common Stock directly owned by VGOD and (iv) 16,903 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker.
    (b)Percent of class:

    The percentages set forth herein are based on (i) 14,543,738 shares of Common Stock outstanding as of November 7, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the "Commission") on November 14, 2025, and (ii) 16,903 shares of Common Stock that the Reporting Persons currently have the right to purchase upon exercise of the Warrants, subject to the Blocker. VGI: 9.99% Opportunities Parent: 9.99% Opportunities GP: 9.3% Opportunities Portfolio GP: 8.8% VGOP: 8.8% KAVRA 104: 0.5% VGOD GP: 0.7% VGOD Portfolio GP: 0.7% VGOD: 0.7% O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 KAVRA 104: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 1,454,608 Opportunities Parent: 1,454,608 Opportunities GP: 1,351,744 Opportunities Portfolio GP: 1,284,726 VGOP: 1,284,726 KAVRA 104: 67,018 VGOD GP: 102,864 VGOD Portfolio GP: 102,864 VGOD: 102,864 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 1,454,608

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 KAVRA 104: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 1,454,608 Opportunities Parent: 1,454,608 Opportunities GP: 1,351,744 Opportunities Portfolio GP: 1,284,726 VGOP: 1,284,726 KAVRA 104: 67,018 VGOD GP: 102,864 VGOD Portfolio GP: 102,864 VGOD: 102,864 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 1,454,608

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:02/17/2026
     
    KAVRA 104 LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of KAVRA 104 LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Drawdown GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
    Date:02/17/2026
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
    Date:02/17/2026
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:02/17/2026
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:02/17/2026
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:02/17/2026

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP (for itself and as manager of KAVRA 104 LLC), and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP (for itself and as manager of KAVRA 104 LLC), and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP (for itself and as manager of KAVRA 104 LLC), and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $INBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INBX

    DatePrice TargetRatingAnalyst
    7/23/2024Mkt Perform
    JMP Securities
    1/23/2024Mkt Outperform → Mkt Perform
    JMP Securities
    3/16/2022$40.00Outperform
    SMBC Nikko
    3/2/2022$53.00 → $40.00Market Outperform
    JMP Securities
    11/10/2021$44.00 → $53.00Outperform
    Credit Suisse
    11/2/2021$46.00 → $53.00Market Outperform
    JMP Securities
    9/21/2021$46.00Market Outperform
    JMP Securities
    More analyst ratings

    $INBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Viking Global Investors Lp sold $11,287,500 worth of shares (350,000 units at $32.25) (SEC Form 4)

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    10/9/25 4:41:40 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Manhard Kimberly

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    5/29/25 4:35:52 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Vuori Kristiina Md

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    5/29/25 4:32:20 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Inhibrx Biosciences

    JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform

    7/23/24 6:28:37 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibrx downgraded by JMP Securities

    JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform

    1/23/24 7:21:49 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SMBC Nikko initiated coverage on Inhibrx with a new price target

    SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00

    3/16/22 7:49:54 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.

    SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)

    2/17/26 4:26:58 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Inhibrx Biosciences Inc.

    SCHEDULE 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)

    2/11/26 1:33:25 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)

    12/16/25 5:00:04 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kayyem Jon Faiz bought $1,523,620 worth of shares (107,186 units at $14.21) (SEC Form 4)

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    11/22/24 4:03:55 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Vuori Kristiina Md bought $100,005 worth of shares (6,667 units at $15.00), increasing direct ownership by 48% to 20,443 units (SEC Form 4)

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    10/7/24 4:34:17 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Lappe Mark bought $629,117 worth of shares (40,000 units at $15.73) (SEC Form 4)

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    9/16/24 5:12:34 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

    SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a brief progress update on the expansion cohorts investigating oze

    12/16/25 5:00:00 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibrx Reports Third Quarter 2025 Financial Results

    SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Recent Corporate Highlights On October 23, 2025, Inhibrx announced positive topline results from its registrational trial

    11/14/25 6:00:00 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibrx Announces Participation in Upcoming Scientific Conferences

    SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry/Academia Precision Oncology & Radmed SymposiumNovember 5th, 2025 – La Jolla, California Title: DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings SarcomaFormat: PresentationPresenters: Josep Garcia, PhD, Executive Vice President, Chief Clin

    11/4/25 4:01:00 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Financials

    Live finance-specific insights

    View All

    Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

    Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key secondary endpoints reinforce the primary benefit, demonstrating meaningful improvements in disease control and patient quality of lifeInhibrx plans to file a BLA in Q2 of 2026Interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates in difficult-to-treat, heavily pretreated patientsManagement to host conference call today at 1:30 p.m. Pacific Time, to review the topline results and ongoing cohortsSAN DIEGO, Oct. 23,

    10/23/25 4:05:00 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

    SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste

    10/4/22 8:00:00 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

    Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de

    5/16/22 9:00:00 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inhibrx Biosciences Inc.

    SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)

    11/14/24 8:14:25 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

    SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

    2/14/24 5:09:31 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

    SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

    2/14/24 5:01:36 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INBX
    Leadership Updates

    Live Leadership Updates

    View All

    Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

    SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma.  We are building a seasoned, world-

    10/28/21 8:30:00 AM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care